Characteristics and Outcomes of HCV Genotype-1-Infected Patients Treated with Peginterferon and Ribavirin Combination Therapy with Discordant HCV Responses 4 and 12 Weeks after Starting Therapy

Hidenori Toyoda\textsuperscript{a}  Takashi Kumada\textsuperscript{a}  Noritomo Shimada\textsuperscript{b}  Koichi Takaguchi\textsuperscript{c}  Tatsuya Ide\textsuperscript{d}  Michio Sata\textsuperscript{d}  Hiroyuki Ginba\textsuperscript{e}  Kazuhiro Matsuyama\textsuperscript{e}  Namiki Izumi\textsuperscript{f}

\textsuperscript{a}Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, \textsuperscript{b}Division of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Matsudo, \textsuperscript{c}Department of Internal Medicine, Kagawa Prefectural Central Hospital, Takamatsu, \textsuperscript{d}Department of Digestive Disease Information and Research, Kurume University School of Medicine, Kurume, \textsuperscript{e}Department of Life Cycle Management, Roche Diagnostics Japan KK, and \textsuperscript{f}Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan

Key Words
Chronic hepatitis C · Peginterferon · Ribavirin · Reduction in HCV RNA levels · Early virologic response · Treatment outcome

Abstract
Objective: Some patients with chronic hepatitis C virus (HCV) infection fail to achieve complete early virologic response (EVR) despite a marked decrease in HCV RNA at 4 weeks. We investigated the characteristics and final treatment outcomes of this patient subpopulation. Methods: A total of 516 patients with HCV genotype 1 were enrolled. Background characteristics and final outcomes were compared between patients who achieved complete EVR and those who did not among patients whose HCV RNA levels decreased 3.0 log\textsubscript{10} or more at 4 weeks. Results: 78 of 334 patients (23.4%) with a ≥3.0 log\textsubscript{10} reduction in HCV RNA levels at 4 weeks failed to achieve complete EVR. Female sex, higher pretreatment HCV RNA levels and lower baseline alanine aminotransferase (ALT) activity were independently associated with failure of complete EVR. The rate of sustained virologic response (SVR) in patients without complete EVR was 47.4%, significantly lower than that in patients with complete EVR (89.7%, p < 0.0001). Conclusions: Female patients, patients with higher pretreatment HCV RNA levels and patients with lower baseline ALT have a high likelihood of failure of complete EVR even when they had a ≥3 log\textsubscript{10} reduction of HCV RNA at 4 weeks, resulting in a significantly lower SVR rate.

Introduction
The combination antiviral therapy with peginterferon (PEG-IFN) and ribavirin has markedly increased the proportion of patients who achieve a sustained virologic response (SVR), i.e. the eradication of hepatitis C virus (HCV), but only approximately 50% of patients infected with HCV genotype 1 achieve an SVR with this therapy. A reduction in serum HCV RNA levels 4 and 12 weeks...
after starting therapy is reportedly important to predict whether patients infected with HCV genotype 1 will ultimately achieve SVR or not with the combination therapy with PEG-IFN and ribavirin, especially when patients underwent the response-guided therapy according to the American Association for the Study of Liver Diseases (AASLD) guidelines. In particular, a reduction in HCV RNA levels 4 weeks after starting therapy is useful for the early prediction of treatment outcome. Several previous studies have reported that patients who achieved a rapid virologic response (RVR), undetectable serum HCV RNA levels 4 weeks after starting therapy, have a high likelihood of achieving SVR [1–4]. In addition to RVR, the degree of reduction in serum HCV RNA levels 4 weeks after starting therapy is useful; a $3.0 \log_{10}$ or more reduction in HCV RNA levels at 4 weeks indicates a high likelihood of achieving SVR even without RVR. Previous studies by Marcellin et al. [5] and our group [6] showed that a $\geq 3.0 \log_{10}$ reduction at 4 weeks is associated with a high likelihood of both achieving a complete early virologic response (EVR), i.e. undetectable serum HCV RNA 12 weeks after starting therapy, and SVR. In both studies, more than 80% of patients who had a $\geq 3.0 \log_{10}$ reduction in serum HCV RNA levels at 4 weeks had complete EVR at 12 weeks. However, some patients did not achieve complete EVR despite a marked decrease in HCV RNA levels at 4 weeks.

In the present study, we attempted to clarify the characteristics and the final treatment outcome of patients who failed to achieve complete EVR at 12 weeks despite a $\geq 3.0 \log_{10}$ decrease in serum HCV RNA levels at 4 weeks among Japanese patients infected with HCV genotype 1b enrolled in a multi-institutional study analyzing changes in serum HCV RNA levels during the course of therapy [7].

**Methods**

**Patients, Treatments, and Evaluation of Responses**

The inclusion criteria for this multi-institutional study were: (1) infection with HCV genotype 1 without co-infection with hepatitis B virus or human immunodeficiency virus; (2) pretreatment HCV RNA levels $\geq 5.0 \log_{10}$ IU/ml, based on a quantitative real-time PCR-based method [8, 9]; (3) standard PEG-IFN and ribavirin combination therapy according to AASLD guidelines [10] started between December 2004 and January 2010 in one of the following five liver centers: Musashino Red Cross Hospital, Kurume University Hospital, Ogaki Municipal Hospital, Shimmatsudo Central General Hospital and Kagawa Prefectural Central Hospital. For 126 patients, the treatment regimen consisted of weekly PEG-IFN-$\alpha_2a$ (Pegasys, Chugai Pharmaceutical, Tokyo, Japan) and daily ribavirin (Copegus, Chugai Pharmaceutical). The other 682 patients were treated with weekly PEG-IFN-$\alpha_2b$ (Pegintron, MSD Co., Tokyo, Japan) and daily ribavirin (Rebetol, MSD Co.). In order to avoid the influence of the PEG-IFN subtype on the association between viral dynamics and treatment outcomes, we excluded patients who had been treated with PEG-IFN-$\alpha_2a$ and ribavirin. In 682 patients who received PEG-IFN-$\alpha_2b$, 516 patients fulfilled the eligibility criteria and were included in the analysis (fig. 1).

Doses of PEG-IFN-$\alpha_2b$ and ribavirin were adjusted based on the patient’s body weight. Patients were given 1.5 μg/kg of PEG-IFN weekly and 10 mg/kg of ribavirin daily. Dose modifications of PEG-IFN or ribavirin were based on the manufacturer’s recommendations.

SVR was defined as undetectable serum HCV RNA 24 weeks after the end of therapy. A patient was considered to have relapsed when serum HCV RNA levels became detectable between the end of treatment and 24 weeks after completion of therapy, although serum HCV RNA levels were undetectable at the end of therapy. A nonresponse was defined as detectable serum HCV RNA 24 weeks after initiation of therapy (i.e. null response or partial nonresponse according to AASLD guidelines). EVR was determined 12 weeks after the start of therapy. Patients were considered to have a complete EVR if serum HCV RNA levels were undetectable 12 weeks after starting therapy. Patients were considered to have a
delayed virologic response if serum HCV RNA levels became undetectable after 12 weeks but until 24 weeks under treatment. RVR was determined 4 weeks after the start of therapy as undetectable serum HCV RNA. Patients were categorized based on the RVR or the degree of reductions in serum HCV RNA levels at 4 weeks. Achievement of complete EVR in patients with RVR or a ≥ 3.0 log_{10} reduction at 4 weeks was further investigated (because pretreatment serum HCV RNA levels were ≥ 5.0 log_{10} IU/ml in all study patients, reduction in HCV RNA levels at 4 weeks of therapy in patients with RVR was ≥ 3.0 log_{10}). Factors associated with the achievement or failure for complete EVR were analyzed, and final treatment outcomes were evaluated based on complete EVR status.

The study protocol was in compliance with the Helsinki Declaration and was approved by the ethics committee of each participating institution. Prior to initiating the study, written informed consent was obtained from each patient to use his or her clinical and laboratory data and to analyze stored serum samples.

Measurements of Serum HCV RNA Levels, Amino Acid Substitution at Residue 70 in the HCV Core, Amino Acid Sequence of the Interferon Sensitivity-Determining Region in HCV NS5A and Genetic Polymorphisms near the IL28B Gene

After obtaining informed consent, serum samples were obtained during the patient’s regular hospital visits: just prior to beginning treatment and every 4 weeks during the treatment period and the 24-week follow-up period after treatment. Serum samples were stored at −80°C until they were analyzed. HCV RNA levels were measured using a quantitative, real-time PCR-based method (COBAS AmpliPrep/COBAS TaqMan HCV Test). The reduction in HCV RNA levels 4 weeks after initiation of therapy was calculated. When calculating the decrease in serum HCV RNA levels, HCV RNA was defined as 0 when HCV RNA was undetectable or HCV RNA was detectable but too low to be unquantifiable.

Amino acid at residue 70 in the HCV core region and the amino acid sequence of the IFN sensitivity-determining region (ISDR, residues 2209–2248 in the NS5A region) were analyzed by direct nucleotide sequencing of each region as previously described [12, 13]. The following PCR primer pairs were used for direct sequencing of the HCV core region:

5′-GCCATAGGTGTCTGCGGAAC-3′ (outer, sense primer),
5′-GGAGCAGTCTCTTGTGACATG-3′ (outer, antisense primer),
5′-GCTAGCCGAGTAGTGT-3′ (inner, sense primer) and
5′-GGAGCAGTCTCTTGTGACATG-3′ (inner, antisense primer).

The following PCR primers were used for direct sequencing of the ISDR:

5′-TTCCACTACGTGACGGGCAT-3′ (outer, sense primer),
5′-CCGTCATGTGACGTGACAT-3′ (outer, antisense primer),
5′-GGGTCAAGCTCCCTGTGAGCC-3′ (inner, sense primer) and
5′-GAGGGTTGGAATCCGGGCGTGC-3′ (inner, antisense primer).

When evaluating the ISDR, HCV was defined as wild type when there were 0 or 1 amino acid substitutions in residues 2209–2248 as compared with the HCV-J strain [14], and as non-wild type when there was more than 1 substitution.

Genotyping of rs8099917 polymorphisms near the IL28B gene was performed using the TaqMan SNP assay (Applied Biosystems, Carlsbad, Calif., USA) according to the manufacturer’s guidelines. A predesigned and functionally tested probe was used for rs8099917 (C_11710096_10, Applied Biosystems). Genetic polymorphisms of rs8099917 reportedly correspond to rs12979860 in more than 99% of individuals of Japanese ethnicity [15]. The TT genotype of rs8099917 corresponds to the CC genotype of rs12979860, the GG genotype of rs8099917 correspond to the TT genotype of rs12979860, and the TG heterozygous genotype of rs8099917 corresponds to the CT genotype of rs12979860.

Statistical Analyses

Quantitative values are reported as means ± standard deviation. Univariate and multivariate analyses using a logistic regression model were performed to identify factors that predict the failure to achieve complete EVR, including age, sex, body mass index, serum
alanine aminotransferase (ALT) activity, γ-glutamyl transpeptidase, liver fibrosis grade, pretreatment HCV RNA levels, amino acid substitution at residue 70 in the HCV core (arginine vs. glutamine or histidine), ISDR amino acid mutations (non-wild type vs. wild type) and genetic polymorphisms near the \textit{IL28B} gene (rs8099917, genotype TT vs. genotype TG or GG). Data analyses were performed using JMP statistical software, version 6.0 (Macintosh version; SAS Institute, Cary, N.C., USA). All p values were two-tailed, and p < 0.05 was considered statistically significant.

### Results

#### Patient Characteristics, HCV RNA Reduction 4 Weeks after Starting Therapy and Complete EVR

Table 1 shows the characteristics of study patients based on the disappearance or the reduction in serum HCV RNA 4 weeks after starting therapy. The prevalence of patients with glutamine or histidine of residue 70 in the HCV core region, those with wild type in the ISDR and those with TG or GG genotype of rs8099917, all of which are reportedly associated with the poorer response to the combination therapy with PEG-IFN and ribavirin, was lower in patients with a ≥3.0 log_{10} reduction including RVR at 4 weeks in comparison to those with a <3.0 log_{10} reduction. Among the 516 patients enrolled in the study, 334 patients (64.7%) showed a 3.0 log_{10} or more reduction in HCV RNA levels 4 weeks after starting therapy. Table 2 shows the rate of complete EVR and SVR according to the reduction in serum HCV RNA levels at 4 weeks of the therapy. At 12 weeks, 256 of 334 patients (76.6%) with a ≥3.0 log_{10} reduction including RVR achieved complete EVR, and the remaining 78 patients (23.4%) failed to achieve complete EVR (fig. 2). The final treatment outcome was SVR in 272 patients (52.7%), 90 patients (17.5%) experienced relapse, and 128 patients (24.8%) had a non-response (48 patients with partial response and 80 patients with null response). Viral breakthrough was observed in 26 patients (5.0%). SVR was achieved in 253 of 334 patients (75.7%) with a ≥3.0 log_{10} reduction in serum HCV RNA levels 4 weeks after starting therapy and 19 of 182 patients (10.4%) with a <3.0 log_{10} reduction in serum HCV RNA levels 4 weeks after starting therapy.

Table 1. Characteristics of patients based on the disappearance or the reduction in serum HCV RNA 4 weeks after starting therapy (n = 516)

<table>
<thead>
<tr>
<th>RVR (n = 116)</th>
<th>≥3.0 log_{10} (n = 218)</th>
<th>&lt;3.0 log_{10} and ≥2.0 log_{10} (n = 61)</th>
<th>&lt;2.0 log_{10} and ≥1.0 log_{10} (n = 58)</th>
<th>&lt;1.0 log_{10} (n = 63)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>56.8±11.1</td>
<td>56.3±11.0</td>
<td>61.7±9.0</td>
<td>60.2±8.6</td>
</tr>
<tr>
<td>Male</td>
<td>55 (47.4)</td>
<td>111 (50.9)</td>
<td>26 (42.6)</td>
<td>24 (41.4)</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>22.9±2.8</td>
<td>23.3±3.3</td>
<td>22.8±3.1</td>
<td>23.2±3.3</td>
</tr>
<tr>
<td>ALT, IU/l</td>
<td>74.9±70.4</td>
<td>57.0±43.6</td>
<td>55.7±34.4</td>
<td>60.6±34.4</td>
</tr>
<tr>
<td>γ-Glutamyl transpeptidase, IU/l</td>
<td>52.9±79.8</td>
<td>41.0±43.9</td>
<td>51.8±44.8</td>
<td>55.3±50.1</td>
</tr>
<tr>
<td>Liver histology-fibrosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F0–1</td>
<td>44 (46.3)</td>
<td>83 (58.0)</td>
<td>22 (45.8)</td>
<td>25 (54.3)</td>
</tr>
<tr>
<td>F2–3</td>
<td>51 (53.7)</td>
<td>60 (42.0)</td>
<td>26 (54.2)</td>
<td>21 (45.7)</td>
</tr>
<tr>
<td>Pretreatment HCV RNA level, log_{10} IU/ml</td>
<td>5.74±0.48</td>
<td>6.35±0.54</td>
<td>6.10±0.51</td>
<td>6.09±0.55</td>
</tr>
<tr>
<td>Amino acid at HCV core 70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arginine</td>
<td>65 (80.2)</td>
<td>153 (85.5)</td>
<td>31 (66.0)</td>
<td>20 (47.6)</td>
</tr>
<tr>
<td>Glutamine or histidine</td>
<td>16 (19.8)</td>
<td>26 (14.5)</td>
<td>16 (34.0)</td>
<td>22 (52.4)</td>
</tr>
<tr>
<td>Mutation of the ISDR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-wild type</td>
<td>39 (39.0)</td>
<td>40 (24.0)</td>
<td>9 (17.3)</td>
<td>10 (21.7)</td>
</tr>
<tr>
<td>Wild type</td>
<td>61 (61.0)</td>
<td>127 (76.0)</td>
<td>43 (82.7)</td>
<td>36 (78.3)</td>
</tr>
<tr>
<td>Genetic polymorphisms near the \textit{IL28B} gene</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>80 (97.6)</td>
<td>173 (96.6)</td>
<td>42 (84.0)</td>
<td>19 (42.2)</td>
</tr>
<tr>
<td>TG or GG</td>
<td>2 (2.4)</td>
<td>6 (3.4)</td>
<td>8 (16.0)</td>
<td>26 (57.8)</td>
</tr>
</tbody>
</table>

Results are expressed as means ± standard deviations or numbers with percentages given in parentheses. Liver histology was not evaluated in 134 patients. Amino acid at residue 70 in the HCV core region, mutation of the ISDR and genetic polymorphisms near the \textit{IL28B} gene (rs8099917) were not evaluated in 118, 98 and 106 patients, respectively.
Factors Associated with the Failure to Achieve Complete EVR in Patients with a $\geq 3.0\ \log_{10}$ Reduction at 4 Weeks

Univariate and multivariate analyses were performed to identify factors associated with the failure to achieve complete EVR at 12 weeks in patients who showed a $\geq 3.0\ \log_{10}$ reduction at 4 weeks (table 3). In univariate analysis, higher pretreatment HCV RNA levels, lower baseline ALT activity, female sex and wild-type ISDR sequence in HCV-NS5A were significantly associated with the failure to achieve complete EVR. In addition, γ-glutamyl transpeptidase had a tendency to be associated with the failure of complete EVR. Factors reportedly associated with the final outcome of combination therapy with PEG-IFN and ribavirin, such as patient age, degree of liver fibrosis, amino acid substitution at residue 70 in the HCV core region and genetic polymorphisms near the $IL28B$ gene, were not associated with failure to achieve complete EVR. In multivariate analysis, higher pretreatment HCV RNA levels, lower baseline ALT activity and female sex were independently associated with failure to achieve complete EVR at 12 weeks.

Treatment Outcomes of Patients Who Failed to Achieve Complete EVR despite a $\geq 3.0\ \log_{10}$ Reduction at 4 Weeks

All 256 patients who achieved complete EVR underwent the 48-week standard treatment regimen according to AASLD guidelines. In 78 patients who did not achieve complete EVR, 70 (89.7%) showed delayed virologic response and underwent the extended 72-week regimen according to AASLD guidelines, and the treatment was discontinued in the remaining 8 patients because of positive serum HCV RNA at 24 weeks. The rate of SVR was 84.4% in patients who achieved complete EVR (SVR, 216 patients; relapse, 30 patients; viral breakthrough, 10 patients). Among 256 patients who achieved complete EVR, the rate of SVR was 85.3% (99 of 116 patients) in patients with RVR and 83.6% (117 of 140 patients) in patients without RVR, being comparable between these two groups. In contrast, the rate of SVR was 47.4% in patients who failed to achieve complete EVR despite a $\geq 3.0\ \log_{10}$ reduction in serum HCV RNA levels at 4 weeks (SVR, 37 patients; relapse, 29 patients; viral breakthrough, 6 patients; partial...
There was no patient who achieved RVR but failed to achieve complete EVR. The rate of SVR was 10.4% in patients who did not show a ≥3.0 log₁₀ reduction at 4 weeks (SVR, 19 patients; relapse, 31 patients; viral breakthrough, 10 patients; partial response, 42 patients; null response, 80 patients; table 2).

Among 334 patients who showed a ≥3.0 log₁₀ reduction in serum HCV RNA levels at 4 weeks including RVR, the rate of SVR was significantly lower in patients who failed to achieve complete EVR than in patients who achieved EVR (p < 0.0001). In patients who did not achieve complete EVR, no differences were found in the distribution of amino acid substitutions at residue 70 of the HCV core region, ISDR amino acid sequences and rs8099917 genotype between patients who achieved SVR and those who did not (data not shown). The rate of SVR was 52.9% in 70 patients who underwent the extended 72-week regimen.

**Discussion**

A rapid reduction in serum HCV RNA levels usually indicates a favorable therapeutic response of infecting HCV and is associated with early disappearance of HCV RNA from the serum during therapy. Indeed, the rate of...
Complete EVR (i.e., disappearance of HCV RNA from serum 12 weeks after starting therapy) was significantly higher in patients with a $\geq 3.0 \log_{10}$ HCV RNA reduction (76.6%) 4 weeks after starting therapy than in patients with a $<3.0 \log_{10}$ HCV RNA reduction (8.8%, $p < 0.0001$; table 2; fig. 2). However, in some patients, serum HCV RNA remains detectable at 12 weeks, when EVR is determined, despite a rapid decrease in HCV RNA levels at 4 weeks.

In the present study, 78 of 334 patients (23.4%) failed to achieve complete EVR despite a $\geq 3.0 \log_{10}$ reduction in HCV RNA levels 4 weeks after starting therapy. The percentage is comparable to that reported by Marcellin et al. [5] and in our previous study [6]. Multivariate analysis indicated that factors associated with this failure include female sex, higher pretreatment HCV RNA levels, and lower baseline ALT activity. Poorer response to PEG-IFN-based antiviral therapy in female patients had been reported with HCV genotype 1b infection [16, 17]. The delayed disappearance of HCV RNA from the serum despite a favorable response of HCV in its early phase may reflect this poorer response associated with female patients. In contrast, baseline host and viral factors that are reportedly strongly associated with the response to the combination therapy [12, 18–20] were not associated with the failure to achieve complete EVR, presumably due to decline of their impact when focusing on patients who achieved $\geq 3.0 \log_{10}$ reduction at 4 weeks.

Indeed, the prevalence of patients with amino acid sequence mutations (glutamine or histidine) at residue 70 of the HCV core region and the prevalence of patients with $\text{IL28B}$ polymorphisms (rs8099917) with GG or heterozygous TG genotypes, both of which are associated with resistance to combination therapy, were very low among the 344 patients who showed a $\geq 3.0 \log_{10}$ reduction in HCV RNA levels at 4 weeks, compared to those with a $<3.0 \log_{10}$ reduction (table 1). The resistance to PEG-IFN and ribavirin combination therapy due to these baseline host and viral factors is associated with early reductions in HCV RNA levels during the first 4 weeks.

The final treatment outcome in patients who did not achieve complete EVR was poorer than in those with achieved complete EVR, despite a $\geq 3.0 \log_{10}$ reduction in HCV RNA levels at 4 weeks. The rate of SVR was below 50%. Even the extended regimen for delayed virologic responders did not markedly improve the rate of SVR. Although the lack of rapid reduction in HCV RNA levels during the early treatment period (first 4 weeks) strongly indicates resistance to therapy, failure to achieve complete EVR further indicates a less favorable outcome. Therefore, viral status at week 12 retains important information to predict the treatment outcome regardless of the reduction in serum HCV RNA at week 4. Given in the emergence of oral direct-acting antivirals in the near future, discontinuation of the therapy may have to be considered for patients who failed to achieve complete EVR due to the low likelihood of achieving SVR. In addition, an extended regimen may also have to be avoided for this patient population, although the rate of SVR was rather higher (65.5%) in patients who did not show a $\geq 3.0 \log_{10}$ reduction at 4 weeks but underwent the extended 72-week treatment regimen because of delayed virologic response.

There are several limitations to this study. The data were based on Japanese patients infected with HCV genotype 1b. Therefore, these results should be confirmed in patients of other ethnicities and patients infected with HCV genotype 1a. In addition, the value of the reduction in HCV RNA levels at 4 and 12 weeks as predictors of SVR should also be evaluated in patients who underwent therapy with PEG-IFN-$\alpha_2a$ and ribavirin. Finally, baseline host and viral factors that are associated with the response to the combination therapy were not available in some patients.

In conclusion, female patients, patients with higher pretreatment HCV RNA levels and patients with lower
baseline ALT activity have a high likelihood of failing to achieve complete EVR at 12 weeks even when they had a ≥3.0 $\log_{10}$ reduction in HCV RNA at 4 weeks. The rate of SVR in this subpopulation was not high despite the achievement of a ≥3.0 $\log_{10}$ reduction at 4 weeks, even when they had a delayed virologic response and under-